![]() 4 Given these findings, as indicated in the National Comprehensive Cancer Network (NCCN) guidelines, octreotide scans are not recommended for surveillance after resection, as an adjunct for tumor staging, or for monitoring the status of advanced disease. Although our report was controversial, a subsequent investigation evaluated the clinical utility of octreotide scans in the diagnosis and management of NET patients and also concluded that it did not alter surgical management. We advocated for the use of octreotide scans to test for the presence of the somatostatin receptor (SSTR) but not to follow the extent of disease. Based on our findings, we concluded that advances made in cross-sectional imaging changed the relative utility of octreotide scans. Octreotide scans, however, identified more asymptomatic and unsuspected bone metastases. 3 In our institutional series of 121 patients, cross-sectional imaging detected more NET soft tissue lesions than octreotide scans. In 2011, our group evaluated the clinical utility of octreotide scans in detecting additional NET lesions as compared to conventional cross-sectional imaging. 1 While octreotide scans have the advantage of whole-body visualization, they also have limitations, including low spatial resolution, uptake of the radiotracer in normal organs, and increased burden on patients requiring multiple visits and scans over 2–3 days. I hope this information helps guide the discussion with your oncologist, Trixie.In 1994, the octreotide scan (somatostatin receptor scintigraphy with 111In-pentetreotide) was approved for imaging of neuroendocrine tumors (NETs) based on studies suggesting that octreotide scans were better at localizing and staging NETs when compared to conventional cross-sectional imaging (computed tomography (CT) and/or magnetic resonance imaging (MRI)). Have they talked about receptors with you? With this information, what questions would you ask your team to help feel confident that they and you are making the best choices? I hope this information helps guide the discussion with your oncologist, Trixie. If a patient's tumor does not have somatostatin receptor type 2 or not enough of them, then the FDG-PET scan (fluorodeoxyglucose-positron emission tomography scan) would be recommended. Some NET tumors may not have enough of these receptors and then the tumor would not be seen by the Ga-68 Dotatate PET. ![]() PET with Ga-68 Dotatate depends on the presence or abundance of a form of receptor on cancer cells, known as somatostatin receptor type 2. However, for some people, it does not work well. I also had the opportunity to ask a Mayo Clinic radiologist and she said that Gallium 68 (Ga-68) Dotatate PET is an excellent imaging for NET tumors. While not a comparison, I found this article from the Neuroendocrine Tumor Research Foundation to be helpful in describing the different NET imaging tests, written for patients: – Imaging Tests for Neuroendocrine Tumors ![]() There are certainly clinical studies about it such as this one: – Comparison of the Impact of 68Ga-DOTATATE and 18F-FDG PET/CT on Clinical Management in Patients with Neuroendocrine Tumors. Finding plain language information comparing relatively new diagnostic tools can be challenging. Hello question is a good one and caused me to search for answers. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |